Sprint Bioscience AB (publ)

STO-SPRINT
Nasdaq Stockholm
Healthcare Biotechnology
Global Rank
#33584
Country Rank
#450
Market Cap
36.62 M
Price
0.335
Change (%)
3.42%
Volume
252,885

Sprint Bioscience AB (publ)'s latest marketcap:

36.62 M

As of 04/30/2026, Sprint Bioscience AB (publ)'s market capitalization has reached $36.62 M. According to our data, Sprint Bioscience AB (publ) is the 33584th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 36.62 M
Revenue (ttm) 18.04 M
Net Income (ttm) 9.89 M
Shares Out 105.52 M
EPS (ttm) 0.11
Forward PE 17.51
Ex-Dividend Date n/a
Earnings Date 05/08/2026
Market Cap Chart
Data Updated: 04/30/2026

Sprint Bioscience AB (publ)'s yearly market capitalization.

Sprint Bioscience AB (publ) has seen its market value grow from kr88.03 M to kr343.98 M since 2014, representing a total increase of 290.77% and an annual compound growth rate (CAGR) of 12.68%.
Date Market Cap(kr) Market Cap(USD) Change (%) Global Rank
06/01/2026 kr343.98 M $37.37 M 121.77% n/a
12/30/2025 kr155.11 M $16.41 M 40.43% 41331
12/30/2024 kr110.46 M $9.93 M -8.82% 38027
12/29/2023 kr121.14 M $11.94 M 449.78% 36313
12/30/2022 kr22.03 M $2.1 M -88.47% 40152
12/30/2021 kr191.05 M $21.02 M 17.26% 32489
12/30/2020 kr162.93 M $0 14.86% 29572
12/30/2019 kr141.86 M $15.08 M -32.15% 27491
12/28/2018 kr209.07 M $23.5 M 29.83% 24753
12/29/2017 kr161.03 M $19.58 M -26.92% 25597

Company Profile

About Sprint Bioscience AB (publ)

Sprint Bioscience AB (publ) is a pharmaceutical company based in Huddinge, Sweden, specializing in the development of innovative cancer treatments. Founded in 2009, the company focuses on advancing therapies through cutting-edge research and drug development.

Key Drug Candidates

  • VPS34: A promising drug candidate designed for treating various cancers using immunotherapies.
  • TREX1: Developed to enhance immuno-oncology, radiotherapy, and chemotherapy in cancer treatment.
  • PETRA01: Another key drug candidate aimed at addressing different forms of cancer.

Research Focus Areas

Beyond its primary drug candidates, Sprint Bioscience is actively engaged in research related to:

  • Tumor metabolism
  • NASH (Non-Alcoholic SteatoHepatitis)

Frequently Asked Questions

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.